Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Capucine Baldini, Armelle Vinceneux, Debbie G.J. Robbrecht, Bernard Doger Doger de Spéville, Karen A. Autio, Michael Thomas Schweizer, Emiliano Calvo, Laura Medina Rodriguez, Marloes Van Dongen, Jean-Laurent Deville, Alice Bernard-Tessier, Debopriya Ghosh, Kristin Michelle Shotts, Pharavee Jaiprasart, Leanne Cartee, Daria Gaut, Josh David Lauring, Sherry Chia-E Wang, Victor Manuel Villalobos, Mark N Stein
Institutions: Institut Gustave Roussy, Centre Léon Bérard, Erasmus MC Cancer Institute, Hospital Universitario Fundación Jiménez Díaz, Memorial Sloan Kettering Cancer Center, University of Washington, Fred Hutch Cancer Center, Hospital Clínico Universitario Virgen de la Victoria, The Netherlands Cancer Institute, Hôpital de la Timone, Université Paris-Saclay, Johnson & Johnson (United States), Columbia University Irving Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Johnson and Johnson
OpenAlex ID: W4410811628